Beta Bionics Q1 net sales up 57% YoY to $27.6M; raises FY 2026 guidance

Beta Bionics, Inc.

2026-Q1 EPS reported -$0.49 revenue$27,626,000

Net sales $27.6M (+57% YoY); PBP channel $10.7M (+181% YoY).
Gross margin 59.5% (+864 bps); loss from ops $24.3M (-88% of sales vs -106%).
Net loss $21.9M vs $28.7M YoY; adjusted EBITDA -$17.7M (-64% vs -88% of sales).
Cash and investments $239.5M; raised full year 2026 guidance (quantified details not provided).
New patient starts declined 10-20% sequentially; 70% from MDI users.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Beta Bionics, Inc. updated its the quarter ended March 31, 2026 guidance (raised).

Period: the quarter ended March 31, 2026
Guidance: raised
Result: reported results

Exact text from the filing

Beta Bionics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026.

View on SEC.gov

1341 earnings releases filed in the last 30 days. Browse all earnings releases →

Beta Bionics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-26-002614

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.